• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

    11/13/24 11:15:11 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BPTH alert in real time by email
    SC 13G/A 1 ea022071803-13ga1intra_bio.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Bio-Path Holdings, Inc.

     

    (Name of Issuer)

     

    Common stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    09057N4097

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 6

     

     

    CUSIP No.          09057N4097

     

         
    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
         
      (a)  ☐  
      (b)  ☐  
         
         
    3. SEC Use Only
         
         
    4. Citizenship or Place of Organization United States of America
         
         
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power

    194,862

       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power

    194,862

         
         
    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    194,862 (see Item 4)

         
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐ 
         
         
    11. Percent of Class Represented by Amount in Row (9)

    4.99% (see Item 4)

         
         
    12. Type of Reporting Person (See Instructions)
       
      IN; HC
       

     

    Page 2 of 6

     

     

    CUSIP No.          09057N4097

     

         
    1. Names of Reporting Persons.
       
      Daniel B. Asher
       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
         
      (a)  ☐  
      (b)  ☐  
         
         
    3. SEC Use Only
         
         
    4. Citizenship or Place of Organization United States of America
         
         
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power

    194,862

       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power

    194,862

         
         
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 194,862 (see Item 4)
         
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
         
    11. Percent of Class Represented by Amount in Row (9) 4.99% (see Item 4)
         
         
    12. Type of Reporting Person (See Instructions)
       
      IN; HC
       

     

    Page 3 of 6

     

     

    CUSIP No.          09057N4097

     

         
    1. Names of Reporting Persons.
       
      Intracoastal Capital LLC
       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
         
      (a)  ☐  
      (b)  ☐  
         
         
    3. SEC Use Only
         
         
    4. Citizenship or Place of Organization Delaware
         
         
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power

    194,862

       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power

    194,862

         
         
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 194,862 (see Item 4)
         
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐ 
         
         
    11. Percent of Class Represented by Amount in Row (9)

    4.99% (see Item 4)

         
         
    12. Type of Reporting Person (See Instructions)
       
      OO
       

     

    Page 4 of 6

     

     

    This Amendment No. 1 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on April 3, 2024 (the “Schedule 13G”).

     

    Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

     

    Item 4.Ownership.

     

    (a) and (b):

     

    As of the close of business on September 30, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 194,862 shares of Common Stock, which consisted of (i) 1,895 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 1”), (ii) 20,825 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 2”), (iii) 3,000 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (“Intracoastal Warrant 3”), (iv) 75,000 shares of Common Stock issuable upon exercise of a fourth warrant held by Intracoastal (“Intracoastal Warrant 4”) and (v) 94,142 shares of Common Stock issuable upon exercise of a fifth warrant held by Intracoastal (“Intracoastal Warrant 5”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 3,710,190 shares of Common Stock outstanding as of October 14, 2024 as reported by the Issuer, plus (2) 1,895 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (3) 20,825 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, (4) 3,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3, (5) 75,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4 and (6) 94,142 shares of Common Stock issuable upon exercise of Intracoastal Warrant 5. The foregoing excludes 30,858 shares of Common Stock issuable upon exercise of Intracoastal Warrant 5 because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 225,720 shares of Common Stock.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote:      0     .

     

    (ii) Shared power to vote or to direct the vote:      194,862     .

     

    (iii) Sole power to dispose or to direct the disposition of      0     .

     

    (iv) Shared power to dispose or to direct the disposition of      194,862     .

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 5 of 6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 13, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher
       
      Intracoastal Capital LLC
       
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

    Page 6 of 6

     

    Get the next $BPTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BPTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BPTH
    SEC Filings

    See more
    • Bio-Path Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

      5/2/25 8:15:15 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Path Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

      4/29/25 4:17:18 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 1-A filed by Bio-Path Holdings Inc.

      1-A - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

      4/11/25 4:28:53 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BPTH
    Leadership Updates

    Live Leadership Updates

    See more

    $BPTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

      HOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today reported the achievement of a third milestone from recent preclinical studies of BP1001-A that provide additional support for its potential as a treatment for obesity. These studies showed BP1001-A rescues the decrease in AKT activity in liver cells and prevents cells from becoming insulin resistant, confirming its potential as a treatment for obesity and related metabolic diseases in Type 2 diabetes patients. A high fat diet

      5/1/25 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Path Holdings Reports Full Year 2024 Financial Results

      HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its financial results for the year ended December 31, 2024 and provided an update on recent corporate developments. "We are merely touching the tip of the iceberg in terms of realizing the potential of our DNAbilize® platform to change the treatment paradigm in both obesity and oncology," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. "Throughout the last year, we built on the bo

      3/28/25 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

      HOUSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today reported results from recent preclinical studies of BP1001-A that support its potential as a treatment for obesity. In these studies, BP1001-A attenuated fatty acid-induced insulin resistance and restored insulin sensitivity in muscle progenitor and skeletal muscle fiber cell models, which signal increased potential for BP1001-A as a treatment for obesity and related metabolic diseases in Type 2 diabetes patients. Updated re

      3/18/25 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Path Holdings Appoints Aline Sherwood to Board of Directors

      HOUSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Aline Sherwood to its Board of Directors on March 31, 2022. Ms. Sherwood replaced Martina Molsbergen, who stepped down from the Board of Directors on February 14, 2022. "We are delighted to welcome Aline to the Bio-Path Board of Directors. With her extensive background in biotechnology communications, Aline synthesizes complex science into compelling messaging, which is instrumental in guiding our communications

      4/6/22 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital initiated coverage on Bio-Path

      Roth Capital initiated coverage of Bio-Path with a rating of Buy

      3/11/21 7:29:52 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH Capital initiated coverage on Bio-Path with a new price target

      ROTH Capital initiated coverage of Bio-Path with a rating of Buy and set a new price target of $13.00

      3/11/21 7:25:18 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Sherwood Aline

      4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

      8/1/24 6:14:31 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aubert Paul

      4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

      8/1/24 6:10:56 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cleaver Heath

      4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

      8/1/24 6:07:55 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Financials

    Live finance-specific insights

    See more
    • Bio-Path Holdings Reports Full Year 2024 Financial Results

      HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its financial results for the year ended December 31, 2024 and provided an update on recent corporate developments. "We are merely touching the tip of the iceberg in terms of realizing the potential of our DNAbilize® platform to change the treatment paradigm in both obesity and oncology," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. "Throughout the last year, we built on the bo

      3/28/25 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Path Holdings Reports Third Quarter 2024 Financial Results

      Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2024 and provided an update on recent corporate developments. "The third quarter was a particularly productive period for Bio-Path as we initiated our obesity program, which marks the first application of our DNAbilize® platform beyond oncology and highlights i

      11/15/24 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

      HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024 and to provide a business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the P

      11/8/24 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

      SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)

      11/13/24 11:15:11 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

      SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)

      11/6/24 4:52:04 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Bio-Path Holdings Inc.

      SC 13G - BIO-PATH HOLDINGS INC (0001133818) (Subject)

      4/3/24 5:44:32 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care